 |
|
|
| |
HEPATITIS C VIRUS REINFECTION AND INJECTING RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR TREATMENT IN PARTICIPANTS ON OPIATE AGONIST THERAPY: C-EDGE CO-STAR PART B
|
| |
| |
Reported by Jules Levin
AASLD Annual Meeting, October 22nd 2017; Washington DC, US
1Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; 2Yale University, New Haven, CT, USA; 3Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA; 4Institute of Clinical Medicine, Akershus University, Oslo, Norway; 5Auckland City Hospital, Auckland, New Zealand; 6Liver Unit, Department of Gastroenterology, Tel Aviv Medical Center, Tel Aviv, Israel; 7Vancouver Infectious Diseases Centre, Vancouver, BC, Canada; 8ID Care, Hillsborough, NJ, USA; 9University of California, San Francisco, San Francisco, CA, USA; 10China Medical University Hospital, Taichung, Taiwan; 11St. Vincent's University Hospital, Melbourne, VIC, Australia; 12Merck & Co., Inc., Kenilworth, NJ, USA
Gregory Dore1, Jason Grebely1, Frederick Altice2, Alain H. Litwin3, Olav Dalgard4, Edward J. Gane5, Oren Shibolet6, Brian Conway7, Ronald Nahass8, Anne Luetkemeyer9, Cheng-Yuan Peng10, David Iser11, Isaias N. Gendrano12, Michelle M. Kelly12, Hsueh-Cheng Huang12, Peggy Hwang12, Eliav Barr12, Michael Robertson12, Heather Platt12
|
| |
|
|
|
|
|
